Abstracts tagged "Biologicals"

Abstract Number: 2473 • ACR Convergence 2023
A Consensus Based Algorithm to Screen for Lung Disease in Children with Systemic Juvenile Idiopathic Arthritis
Holly Wobma¹, Ronny Bachrach², Joseph Farrell², Margaret Chang³, Megan Day-Lewis¹, Fatma Dedeoglu¹, Martha Fishman⁴, Olha Halyabar¹, Claudia Harris¹, Daniel Ibanez¹, Liyoung Kim¹, Timothy Klouda⁴, Katie Krone⁴, Pui Lee¹, Mindy Lo¹, Kyle McBrearty¹, Esra Meidan¹, Susan Prockop⁵, Aaida Samad⁴, Mary Beth Son¹, Peter Nigrovic³, Alicia Casey⁴, Joyce Chang³ and Lauren Henderson³, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Community Member, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Division of Pulmonary Medicine, Boston Children’s Hospital, Boston, MA, ⁵Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA
Background/Purpose: Over the last decade, lung disease (LD) has become an increasingly recognized complication of systemic juvenile idiopathic arthritis (sJIA). Children with sJIA-LD may be…
Abstract Number: 0340 • ACR Convergence 2023
Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study
Chiara Gasteiger¹, Maria Lobo², Robin Stanley¹, Lun Shen Wong¹, Rachel Murdoch¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand
Background/Purpose: Patients are frequently transitioned to biosimilars to reduce the cost burden of biologics. Brand changes can be daunting for patients who have concerns about…
Abstract Number: 0429 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Andrew Garrison⁶, Yanna Song⁶, Sara K. Penn⁶, Ralph Lippe⁷, Diane Caballero⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Inc., Chicago, IL, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…
Abstract Number: 0540 • ACR Convergence 2023
The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study
Angela Crowley¹, Lori Siegel¹, Pendleton Wickersham², Heather Jones³, Dan Webster⁴, Anna Shmagel⁵, Ana Biljan⁶, Uta Kiltz⁷ and Philip Helliwell⁸, ¹Illinois Bone and Joint Institute, Gurnee and Hinsdale, IL, ²Methodist Hospital, Baptist Medical Center and CHRISTUS Santa Rosa Hospital - Westover Hills, San Antonio, TX, ³AbbVie, Inc., Mettawa, IL, ⁴AbbVie, Inc., Libertyville, IL, ⁵AbbVie, Inc., Long Grove, IL, ⁶AbbVie, Inc., Buffalo Grove, IL, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients (pts) with AS, higher BMI has been linked to higher disease activity1. However, given that BMI can be a poor indicator of…
Abstract Number: 0777 • ACR Convergence 2023
Characteristics of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis
Cecile PHILIPPOTEAUX¹, Anne Marty-Ane¹, Emeline Cailliau¹, Peggy Philippe¹, Bernard Cortet¹, Julien Paccou¹, Rene-Marc Flipo¹ and Jean-Guillaume Letarouilly², ¹University Hospital Center of Lille, Lille, France, ²CHU Lille, Lille, France
Background/Purpose: The EULAR task force recently published the difficult-to-treat RA (D2T RA) definition [1], however, a definition of D2T PsA is still lacking. To date,…
Abstract Number: 1090 • ACR Convergence 2023
Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center
Shelby Gomez¹, Trisha Ludwig¹, Katherine Hartkopf², Sancia Ferguson³, Lori Zemlicka⁴, Mindy Jones⁵ and Christie M. Bartels⁶, ¹UW Health Pharmacy, Madison, WI, ²Pharmacy Society of Wisconsin, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴UW Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: We embedded a clinical pharmacist into our university rheumatology clinics beginning in June 2022 to improve patient experience and reduce provider burden based on…
Abstract Number: 1328 • ACR Convergence 2023
Switching Biologics or Janus Kinase Inhibitors Is Effective in Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation
Katsuaki Onishi¹, Yutaro Yamada², Tadashi Okano², Kenji Mamoto², Shohei Anno³, Tatsuya Koike⁴ and Hiroaki Nakamura², ¹Baba Memorial Hospital, Osaka, Japan, ²Osaka Metropolitan University, Osaka, Japan, ³Yodogawa Christian Hospital, Osaka, Japan, ⁴Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: Although biologics (BIO) or Janus kinase inhibitors (JAKi) have improved treatment for rheumatoid arthritis (RA), there are patients with difficult disease activity control even…
Abstract Number: 1498 • ACR Convergence 2023
First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Giorgio Senaldi¹, Aparna Mohan¹, Li Zhang¹, Jun Tanaka², Grishma Pandya³, Sindee Grossman³, Sarah Urbina⁴, Steven Reynolds⁵ and Alan Hand⁴, ¹Daiichi Sankyo, Basking Ridge, NJ, ²Daiichi Sankyo, Inc., Basking Ridge, NJ, ³Daiichi Sankyo Inc., Basking Ridge, NJ, ⁴Worldwide Clinical Trials, San Antonio, TX, ⁵Cenexel, Los Alamitos, CA
Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor, whose ligands include nucleic acids and whose activation is part of the pathogenesis of systemic lupus…
Abstract Number: 1702 • ACR Convergence 2023
Outcomes in Systemic Sclerosis Patients Treated with Rituximab and Mycophenolate Mofetil Combination Therapy Compared to Autologous Hematological Stem Cell Transplantation
shiri keret¹, Lisa Kaly², Aniela Shouval², Tsila Zuckerman³, Israel Henig⁴, Abid Awisat⁵, Itzhak Rosner⁶, Michel Rozenbaum², Nina Boulman², Yair Molad⁷, ariela Dortort Lazar⁸, Gleb Slobodin² and Doron Rimar², ¹Bnai Zion, Atlit, Israel, ²Bnai Zion Medical Center, Haifa, Israel, ³Hematology department, Rambam Medical Center, Haifa, Israel, ⁴Stem cell transplantation unit, Hematology department, Rambam Medical Center, Haifa, Israel, ⁵Bney-Zion Medical Center, Baqa Elgharbiya, Israel, ⁶Bnai Zion Medical Center/Technion, Haifa, Israel, ⁷Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁸Rabin Medical Center and Tel Aviv university, Tel Aviv, Israel
Background/Purpose: Autologous hematological stem cell transplantation (AHSCT) is a grade A therapy for early diffuse progressive systemic sclerosis (SSc), that has been validated in three…
Abstract Number: 2163 • ACR Convergence 2023
Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?
Joy van der Pol¹, Sytske Anne Bergstra², Thomas Huizinga² and CF Allaart², ¹Leiden University Medical Center, Utrecht, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The EULAR recommendations for the treatment of RA state, by expert opinion, that if a treatment target is not achieved with the first csDMARD…
Abstract Number: 2244 • ACR Convergence 2023
Switching Between Biologics and Targeted Synthetic Therapies Due to Inefficacy in Psoriatic Arthritis
Dalifer Freites Núñez¹, Maria Rodriguez Laguna¹, Cristina Hormigos martín¹, zulema Rosales², Leticia Leon³, Gloria Candelas¹, Daniel Rubio⁴, Jose Otazu¹, Benjamin Fernandez¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ⁴Complutense University, Madrid, Spain
Background/Purpose: Biological and targeted synthetic therapies (ts/bDMARDs) have transformed the management ofPsoriatic arthritis (PsA).However, PsA might experience ts/bDMARD failure, (mainly due to inefficacy), and switching…
Abstract Number: 2474 • ACR Convergence 2023
Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience
Ilaria Maccora¹, Valerio Accardo², Marco Cattalini³, ilaria Pagnini⁴, Andrea Taddio⁵, Edoardo Marrani⁶, francesco La Torre⁷, Matteo Trevisan⁸, Maria Vincenza Mastrolia⁹ and Gabriele Simonini¹⁰, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²University of Florence, Florence, Italy, ³Spedali Civili di Brescia, Brescia, Italy, ⁴Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, ⁶University of Florence, Firenze, Italy, ⁷Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, ⁸IRCCS Burlo Garofalo, Trieste, Italy, ⁹NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁰Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
Abstract Number: 032 • 2023 Pediatric Rheumatology Symposium
From Bedside to Bench and Back: Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes with Hearing Loss as the Primary Presentation, Responsive to Anti-IL1 Therapy
Merav Birk-Bachar¹, Hadar Cohen², Yoel Levinsky³, rotem tal⁴, Gil Amarilyo⁵, Meirav Sokolov⁶, Efrat Sofrin-Drucker⁷, Naama Orenstein⁷, Gabriel Lidzbarsky⁷, Liora Kornreich⁸, Eyal Raveh⁶, Nesya Kropach-Gilad⁷, Motti Gerlic² and Liora Harel⁹, ¹Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ²Sackler Faculty of Medicine, Immunology Department, Tel Aviv University, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ⁴Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁵Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁶Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁷Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel, ⁸Pediatric Imaging Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel
Background/Purpose: Cryopyrin-associated periodic syndromes (CAPS) are a spectrum of rare autoinflammatory diseases caused by gain-of-function mutations inthe NLRP3 gene. These mutations cause inflammasome hyperactivity and…
Abstract Number: 073 • 2023 Pediatric Rheumatology Symposium
Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy
Claire Yang¹, Natalie Rosenwasser², Xing Wang², Zheng Xu², Joshua Scheck², Ramesh Iyer³ and Yongdong (Dan) Zhao³, ¹University of Washington School of Medicine, Seattle, WA, ²Seattle Children's Hospital, seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an autoinflammatory bone disease requiring immunosuppressive therapy in half of patients. Monoclonal Tumor Necrosis Factor inhibitors (TNFi) are…
Abstract Number: 109 • 2023 Pediatric Rheumatology Symposium
Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients
Ana Isabel Rebollo-Giménez¹, Luca Carlini², Yulia Vyzhga³, Silvia Rosina⁴, Ekaterina Alexeeva⁵, Charlotte Myrup⁶, Silvia Magni Manzoni⁷, Maria Trachana⁸, Valda Stanevicha⁹, Constantin Ailioaie¹⁰, Elena Tsitsami¹¹, Alexis-Virgil Cochino¹², Chiara Pallotti¹³, Silvia Scala¹³, Angela Pistorio¹⁴, Sebastiaan Vastert¹⁵, Joost F. Swart¹⁶ and Nicolino Ruperto¹⁷, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattia Infiammatorie, Genova, Italy, ⁴IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Federal State Autonomous Institution “National Medical Research Center of Children's Health”, Ministry of Health of the Russian Federation, Moscow, Russia, ⁶Rigshospitalet, Pediatric rheumatology unit 4272, Copenhagem, Denmark, ⁷IRCCS Ospedale Pediatrico Bambino Gesù, Division of Rheumatology, Roma, Italy, ⁸Hippokration General Hospital, Thessaloniki University School of Medicine, First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Thessaloniki, Greece, ⁹Riga Stradins University, Children University Hospital, Riga, Latvia, ¹⁰Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ¹¹Aghia Sophia Childrens Hospital, First Department of Pediatrics, University of Athens Medical School, Athens, Greece, ¹²Institute for Mother and Child Care, Pediatrics, Bucharest, Romania, ¹³IRCCS Istituto Giannina Gaslini, U.O.C. Pediatric and Rheumatology Clinic, PRINTO, Genova, Italy, ¹⁴IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, ¹⁵Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁶Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, Netherlands, ¹⁷IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, PRINTO, Genova, Italy
Background/Purpose: The better understanding of systemic Juvenile Idiopathic Arthritis (sJIA) pathogenesis and availability of new drugs, such as biologic disease-modifying anti-rheumatic drugs (bDMARDs) specifically dedicated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].